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THE aim  of  the  present  study  was  to  compare  the
effects of selective phosphodiesterase (PDE) 3, 4 and
5  inhibitors  on  antigen-induced  airway  hyperre-
sponsiveness  in  sensitized  guinea-pigs.  When  the
sensitized  guinea-pigs  were  orally  pre-treated  with
the selective PDE4 inhibitor, Ro 20–1724 (30 mg/kg),
and  studied  48h  after  OA,  a  significant  reduction
(P<0.01) of the leftward shift  of the dose–response
curve to ACh was noted, whereas it was ineffective at
the  lower  dose  (10 mg/kg).  Administration  of  the
selective  PDE3 inhibitor,  milrinone  (30 mg/kg)  also
elicited a significant reduction (P<0.01) of the airway
hyperresponsiveness,  whereas  the  PDE5  inhibitor
zaprinast  (30 mg/kg)  was  ineffective.  These  results
show that both PDE3 and PDE4 inhibitors are able to
inhibit the antigen-induced airway hyperresponsive-
ness in sensitized guinea-pigs and support the poten-
tial utility of selective PDE inhibitors in the treatment
of asthma.
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Introduction
Bronchial asthma is a disease characterized by varia-
ble airway  obstruction and airway  hyperresponsive-
ness  that  has been  linked to  mucosal  inflammation
and particularly, the influx and activation of eosino-
phils.1 One way to reduce the development of airway
hyperresponsiveness  is  to  inhibit  the  associated
inflammation  by  anti-inflammatory  drugs.  However,
under certain conditions, airway hyperresponsiveness
has  been  observed  despite  the  absence  of  any
inflammatory  process,  such  as  eosinophil  recruit-
ment.  We  have  previously  demonstrated  that  sub-
stance P is able to induce airway hyperresponsiveness
not associated with eosinophil recruitment, but with
an enhancement of alveolar macrophage activation.2
The  cyclic  nucleotides,  cyclic  adenosine  monop-
hosphate (cyclic AMP) and cyclic guanosine monop-
hosphate  (cyclic  GMP),  are  important  second  mes-
sengers  of  cellular  function.  Phosphodiesterases
(PDEs)  are  a  group  of  enzymes  that  regulate  the
breakdown of cyclic nucleotides. Among PDEs, PDE3
and PDE4  appear to be the most important  for the
regulation of cyclic AMP, whereas PDE5 is responsible
for  the  level  of  intracellular  cGMP.  As  far  as  anti-
inflammatory drugs are concerned, much attention has
been focused on the therapeutic potential of selective
PDE4 inhibitors (for review see Refs 3 and 4). It has also
been frequently reported that PDE3 inhibitors do not
have potent anti-inflammatory effects. This has been
clearly  demonstrated  on  eosinophil  recruitment
induced by antigen challenge, PAF aerosol exposure or
intratracheal administration of IL-5.5,6 This is probably
due  to  the  fact  that  in  most  inflammatory  cells,
including eosinophils, the low Km cyclic AMP-specific
members of the PDE4 family are the most prominently
expressed.4,7 However, in mononuclear cells, PDE3 is
also involved in the regulation of cyclic AMP levels. In
macrophages, in the presence of the adenylyl cyclase
activator,  PGE2,  PDE3  inhibitors  are  as  effective  as
PDE4-selective drugs in inhibiting TNF-a release.8 We
also  recently  demonstrated  that  PDE3  and  PDE4
isoenzymes are present in alveolar macrophages from
sensitized guinea-pigs and that PDE4, but also PDE3,
regulate the release of inflammatory mediators.9
Numerous studies have reported the actual efficacy
of PDE inhibitors, namely selective PDE4  inhibitors,
on the development  of airway hyperresponsiveness.
However  the  effects  of  PDE3  inhibitors  appear
controversial.10–15
The  present  study  was  undertaken  in  order  to
compare  the  effect  of  milrinone,  a  selective  PDE3
inhibitor, Ro 20–1724, a selective PDE4 inhibitor, and
zaprinast, a selective PDE5 inhibitor, on the develop-
ment of airway hyperresponsiveness in sensitized and
challenged guinea-pigs.
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Materials
The  following  drugs  were  used  :  ovalbumin  (OA,
chicken egg, grade V) and milrinone (Sigma, St. Louis,
MO,  USA),  Ro  20–1724  (RBI,  Natick,  MA,  USA),
urethane  (ethylcarbamate,  Prolabo,  Paris,  France),
pancuronium  bromide  (Pavulon,  Organon,  Fresnes,
France).  Racemic  rolipram  was  synthesized  at  the
Institut de Recherche Jouveinal/Parke-Davis, Fresnes,
France.  Zaprinast  was  a  generous  gift  of  Rhˆ one-
Poulenc Rorer (UK).
Sensitization  procedure  and  challenge
Specific  pathogen-free  male  Hartley  guinea-pigs
(300–350 g,  Charles  River,  St.  Aubin  les  Elboeuf,
France) were used throughout the study. Following
purchase, they were housed in our standard animal
care facilities. All guinea-pigs were fed standard pellet
(UAR, Villemoisson-Sur-Orge, France) and given water
ad  libitum.  Guinea-pigs  were  sensitized  and  chal-
lenged as previously described.16 Briefly, they were
placed in a Plexiglas chamber (30 3 50 3 30cm) and
exposed twice for 30min to an aerosol of ovalbumin
(OA)  2 mg/ml  in  saline  (NaCl,  0.9  %),  with  a  48-h
interval. The  aerosol  was  generated  by  a  Devilbiss
ultrasonic nebulizer (Aerodynamic mean mass median
particle diameter of 0.5–5 m M, ULTRA-NEB 99, Som-
merset, PA, USA). Fifteen to 20 days after the initial
sensitization  procedure,  the  guinea-pigs  were  chal-
lenged by 15-min exposures to five successive solu-
tions  of  OA  of  respectively  10 m g/ml,  100 m g/ml,
1 mg/ml, 5mg/ml and 10 mg/ml. Control guinea-pigs
were exposed to a saline solution for an equivalent
period of time.
Assessment of  airway  hyperresponsiveness
Bronchopulmonary  reactivity  to  acetylcholine  was
assessed 48 h after antigen challenge or saline expo-
sure.  Guinea-pigs  are  anaesthetized  (urethane,
1.2 g/kg,  i.p.)  and  placed  in  a  dorsal  recumbent
position. A trachea cannula was inserted and the lungs
were  mechanically  ventilated  with  a  constant  tidal
volume (1ml laboratory air/100 g body weight) with a
respiratory  pump  (Ugo  Basile,  Varese,  Italy,  60
breaths/min). Spontaneous  breathing  was abolished
with pancuronium bromide (2 mg/kg), injected in the
posterior penis vein. Airway inflation pressure (AIP),
an  index  of  intrathoracic  airway  caliber,  was  mon-
itored from a lateral port of the ventilator circuit using
a Ugo basile bronchospasm transducer according to
the previously described method.16
After a 10-min equilibration period, three succes-
sive  1-min  aerosol  administrations  of Ach  (50,  100,
200  and  500 m g/ml)  were  performed  at  10-min
intervals  with  constant  monitoring  of  the  airway
inflation  pressure. The  aerosol  was  generated  by  a
Devilbiss  ‘Pulmosonic’  ultrasonic  nebulizer  perma-
nently connected in series with the afferent limb of
the  ventilator  circuit. The  airway  inflation  pressure
was  expressed  as  percent  change  over  the  100%
obtained by clamping the tracheal cannula at the end
of the experiment.
Protocol
All  drugs  were  prepared  extemporaneously  in  dis-
tilled  water  containing  5%  Arabic  gum.  Sensitized
guinea-pigs  were  treated  orally  with  either  Ro
20–1724 (10 or 30 mg/kg) or milrinone (30 mg/kg) or
zaprinast (30 mg/kg), 24 and 3 h before the antigen
challenge or saline exposure.
Data  analysis
Results are expressed as means±SEM. Statistical differ-
ences  between  the  dose-responses  to  Ach  in  the
groups receiving the various treatment were analyzed
by two-way analysis of variance. It was thus possible
to examine the whole dose–response curves obtained
in these different groups of animals.
Results
Exposure of anaesthetized guinea-pigs to the succes-
sive  aerosols  of ACh  (50,  100,  200  and  500 m g/ml)
induced a dose-related bronchopulmonary response.
When the animals were previously  exposed to  OA,
the  dose–response  curve  to  ACh  was  significantly
shifted to the left (P<0.001) (Figs 1–4).
When  the  sensitized  guinea-pigs  were  pretreated
with Ro 20–1724 (30 mg/kg), and studied 48 h after
OA, a significant reduction (P<0.05) of the leftward
shift of the dose–response curve to ACh was noted
(Fig. 1), whereas no effect was observed at the lower
dose (10mg/kg) (Fig. 2).
Administration  of  milrinone  (30 mg/kg)  also  eli-
cited a significant reduction (P<0.05) of the leftward
shift  of  the  dose–response  curve  to ACh  after  OA
challenge (Fig. 3), whereas, zaprinast (30 mg/kg) had
no effect (Fig. 4).
Discussion
The  present  study  demonstrated  that  the  selective
PDE4 inhibitor, Ro 20–1724 and the selective PDE3
inhibitor,  milrinone,  but  not  the  selective  PDE5
inhibitor,  zaprinast, are able to  inhibit  the develop-
ment  of  airway  hyperresponsiveness  induced  by
antigen challenge in sensitized guinea-pigs.
Airway  hyperresponsiveness  induced  by  antigen
challenge  is  generally  associated  in  humans  and  in
experimental animals with an influx of inflammatory
cells in lung tissue1,16 and the activation of resident
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We have also reported that macrophages recovered in
the  BAL  fluid  of  either  saline-exposed  or  OA-chal-
lenged sensitized guinea-pigs exhibit a PDE type 3 and
a PDE type 4 isoenzyme activity.9 It can therefore be
suggested that the profile of PDE activities in macro-
phages may influence the activity of PDE inhibitors.
In this regard, we observed that the combination of
milrinone and the selective PDE4 inhibitors, rolipram
or Ro 20–1724 had a significant inhibitory effect on
arachidonate release.9 We recently proposed that the
reduced  activity  of  alveolar  macrophages  may  be
involved  in  the  inhibition  of  the  development  of
airway hyperresponsiveness by both PDE3 and PDE4
inhibitors  and  suggest  that  activation  of  alveolar
macrophages is a key event in the bronchopulmonary
alterations that follow antigen challenge.
Such a hypothesis is not consistent with the fact
that the development of airway hyperresponsiveness
is closely associated with eosinophil influx in airways.
We  and  others  have  previously  demonstrated  that
PDE4 inhibitors, but not PDE3 inhibitors, are able to
reduce the eosinophil recruitment induced either by
antigen  challenge  in  sensitized  guinea-pigs5,19 or
administration of chemotactic factor, such as PAF and
IL-5  in  naive  guinea-pig s.5,6 This  would  suggest  a
dissociation between eosinophil recruitment and the
development  of  airway  hyperresponsiveness.  This
dissociation takes into account the fact that eosino-
phils do not contain PDE3 isoenzyme,4 and then that
PDE3 inhibitors are not able to block mediator release
from  these  inflammatory  cells.19 This  hypothesis  is
also strengthened by the results obtained with aerosol
exposure of guinea-pigs to substance P. Indeed, the
development of airway hyperresponsiveness induced
by aerosol administration of substance P is associated
with  alveolar  macrophage  activation  rather  than
granulocyte recruitment.2 A proposed mechanism for
the  inhibition  of  antigen-induced  airway  hyperre-
sponsiveness by  PDE  inhibitors  is the regulation  of
cyclic  AMP  by  PDE3  and  4  contributing  to  the
modulation of neuronal sensitivity in the airways and
of tachykinin release.20,21
It  is  now  generally  accepted  that  selective  PDE4
inhibitors are able to reduce airway hyperresponsive-
ness,  and  that  this  effect  is  associated  with  anti-
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FIG. 1. Influence of Ro 20± 1724 (30mg/kg) on cumulative
dose± response curve for acetylcholine (50, 100, 200 and
500m g/ml) in anaesthetized  guinea-pigs,  24h after ovalbu-
min challenge (OA). Sensitized guinea-pigs were treated
orally with Ro 20± 1724 (30mg/kg), 24 and 3h before the
antigen  challenge  (OA) or saline  exposure  (SAL). Symbols
represent control with (h ) or without (s ) Ro 20± 1724  and
after OA challenge with (j ) or without (d ) Ro 20± 1724
(n=6± 20).  Significant  difference  between  OA  and  Ro
20± 1724+OA is P<0.05. No significant difference is noted
between  SAL+Ro  20± 1724  and  OA+Ro  20± 1724.
FIG. 2. Influence of Ro 20± 1724 (10mg/kg) on cumulative
dose± response curve for acetylcholine (50, 100, 200 and
500m g/ml) in anaesthetized  guinea-pigs,  24h after ovalbu-
min challenge (OA). Sensitized guinea-pigs were treated
orally with Ro 20± 1724 (10mg/kg), 24 and 3h before the
antigen  challenge  (OA) or saline  exposure  (SAL). Symbols
represent control with (h ) or without (s ) Ro 20± 1724  and
after  antigen  challenge  with  (j )  or  without  (d )  Ro  20± 1724
(n=4± 20).  No  significant  difference  is  noted  between  OA  and
OA+Ro 20± 1724. Significant difference between SAL+Ro
20± 1724  and  Ro  20± 1724+OA  is  P<0.05.inflammatory activities.10–12,21 However, recent stud-
ies have reported the effects of two PDE3 inhibitors.
Using cilostazol, Uno and colleagues15 have reported
an inhibition of LPS-induced bronchial hyperreactivity
in  guinea-pigs,  and  Fujimura  et  al.13 a  reduced
bronchial hyperresponsiveness in asthmatic patients.
Finally, Bardin et al.14 have reported that the selective
PDE3  inhibitor,  MKS492,  is  able  to  prevent  early
bronchoconstrictor  response  in  asthma  and  attenu-
ates late response.
Since  PDE3  inhibitors  have  bronchodilator  and
bronchoprotective  properties,22 it  can  also  be  sug-
gested that the bronchoprotective effect observed in
these latter studies was due to their relaxant activity
on  smooth  muscles.23 In  the  present  study,  we
excluded such a possibility since the bronchopulmo-
nary  response  induced  by  acetylcholine  was  not
modified by milrinone in unchallenged animals.
In conclusion, the present study showed that PDE3
(milrinone) and  PDE4  inhibitors (Ro 20–1724),  but
not the PDE5 inhibitor (zaprinast), are able to reduce
the  development  of  airway  hyperresponsiveness  in
sensitized guinea-pigs and suggests that this group of
selective compounds may have a role to play in the
treatment of asthma.
ACKNOWLEDGEMENTS. The authors thank Guy Bou¨ er for his assistance in
preparing the manuscript.
References
1. Holgate ST, Djukanovic R, Wilson J, Roche W, Roche PH, Howarth PH.
Inflammatory processes and bronchial hyperresponsiveness. Clin Exp
Allergy 1991; 21 (Suppl 1): 30–36.
2. Boichot E, Lagente V , Paubert-Braquet M, Frossard N. Inhaled substance P
induces  activation  of  alveolar  macrophages  and  increases  airway
responses in the guinea-pig. Neuropeptides 1993; 25: 307–313.
3. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase
(PDE)4  inhibitors:  anti-inflammatory  drugs  of  the  future?  Trends
Pharmacol Sci 1997; 18: 164–171.
4. Torphy TJ.  Phosphodiesterase  isozymes.  Molecular  targets  for  novel
antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351–370.
5. Lagente V , Moodley I, Perrin S, Mottin G, Junien JL. Effects of isozyme-
selective phosphodiesterase inhibitors on eosinophil infiltration in the
guinea-pig lung. Eur J Pharmacol 1994; 255: 253–256.
6. Lagente V , Pruniaux MP , Junien JL, Moodley I. Modulation of cytokine-
induced  eosinophil infiltration by  phosphodiesterase inhibitors. Am J
Respir Crit Care Med 1995; 151: 1720–1724.
7. Beavo JA, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodies-
terases. Mol Pharmacol 1994; 46: 399–405.
8. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro
differentiation of human  monocytes  to  macrophages: change  of  PDE
profile  and  its relationship  to  suppression of  tumor  necrosis factor-a
release by PDE inhibitors. Br J Pharmacol 1997; 121: 221–231.
9. Germain N, Bertin B, Legendre A, Martin B, Lagente V , Payne A., Boichot
E.  Selective  phosphodiesterase  inhibitors  modulate  the  activity  of
alveolar macrophages from sensitized guinea-pigs. Eur Respir J 1998; 12:
1334–1339.
N. Germain et al.
156 Mediators  of  Inflammation  ´  Vol  8  ´  1999
FIG. 3. Influence of milrinone (30mg/kg) on cumulative
dose± response curve for acetylcholine (50, 100, 200 and
500m g/ml) in anaesthetized  guinea-pigs,  24h after ovalbu-
min challenge (OA). Sensitized guinea-pigs were treated
orally with milrinone (30mg/kg), 24 and 3h before the
antigen  challenge  (OA) or saline  exposure  (SAL). Symbols
represent  control  with  (h )  or  without  (s )  milrinone  and  after
antigen  challenge  with  (j )  or  without  (d )  milrinone
(n=6± 20). Significant difference between OA and milrino-
ne+OA  is  P<0.05.  No  significant  difference  is  noted  between
SAL+milrinone  and  OA+milrinone.
FIG.  4.  Influence  of  zaprinast  (30mg/kg)  on  cumulative  dose±
response  curve  for  acetylcholine  (50,  100,  200  and  500m g/ml)
in anaesthetized guinea-pigs, 24h after ovalbumin chal-
lenge.  Sensitized  guinea-pigs  were  treated  orally  with  zapri-
nast  (30mg/kg),  24  and  3h  before  the  antigen  challenge  (OA)
or  saline  exposure  (SAL).  Symbols  represent  control  with  (h )
or  without  (s )  zaprinast  and  after  antigen  challenge  with  (j )
or  without  (d )  zaprinast  (n=5± 20).  No  significant  difference  is
noted  between  OA  and  OA+zaprinast.  Significant  difference
between  SAL+Ro  20± 1724  and  zaprinast+OA  is  P<0.01.10. Howell  RE,  Sickels  BD,  Woeppel  SL.  Pulmonary  antiallergic  and
bronchodilator effects of isozyme-selective phosphodiesterase inhibitors
in guinea-pigs. J Pharmacol Exp Ther 1993; 264: 609–615.
11. Ortiz JL, Valles  JM,  Marti-Cabrera  M, Cortijo J,  Morcillo EJ.  Effects  of
selective phosphodiesterase inhibitors on platelet-activating factor- and
antigen-induced  airway  hyperreactivity,  eosinophil  accumulation  and
microvascular  leakage  in  guinea-pigs.  Naunyn  Schmiedebergs  Arch
Pharmacol 1996; 353: 200–206.
12. Danahay H, Broadley KJ. Effects of inhibitors of phosphodieterase, on
antigen-induced bronchial hyperreactivity in conscious sensitized guinea-
pigs  and  airway  leukocyte  infiltration.  Br  J  Pharmacol 1997;  120:
289–297.
13. Fujimura  M,  Kamio  Y,  Myou  S,  Hashimoto T ,  Matsuda  T.  Effect  of
phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsive-
ness in elderly patients with asthma. Int Arch Allergy Immunol 1997;
114: 379–384.
14. Bardin  PG,  Dorward  MA,  Lampe  FC,  Franke  B,  Holgate  ST .  Effect  of
selective phosphodiesterase 3 inhibition on the early and late asthmatic
responses to inhaled allergen. Br J Clin Pharmacol 1998; 45: 387–391.
15. Uno T, Tanaka H, Nagai H. Effects of isoenzyme selective phosphodiester-
ase inhibitors on bacterial lipopolysaccharide-induced bronchial hyper-
reactivity in guinea-pigs. Gen Pharmacol 1998; 30: 167–173.
16. Boichot E, Lagente V, Carre C, Waltmann P, Mencia-Huerta JM, Braquet P.
Bronchial hyperresponsiveness and  cellular infiltration in the lung of
guinea-pigs sensitized and challenged by aerosol. Clin Exp Allergy 1991;
21: 67–76.
17. Tonnel AB,  Gosset  P, Joseph  M, Fournier  E, Capron A. Stimulation of
alveolar macrophages in asthmatic patients after local provocation tests.
Lancet 1983; i: 1406–1408.
18. Lagente V , Boichot E, Chadli S, Dugas B, Mencia-Huerta JM, Braquet P.
Effect  of  the  platelet-activating  factor  antagonist,  BN  50730,  on  the
increased  production  of superoxide  anions by  alveolar  macrophages
from  antigen-exposed  sensitized  guinea-pigs.  Fund  Clin  Pharmacol
1991;  5:  426.
19. Banner  KH,  Page  CP .  Theophylline  and  selective  phosphodiesterase
inhibitors  as  anti-inflammatory  drugs  in  the  treatment  of  bronchial
asthma. Eur Respir J 1995;  8: 896–1000.
20. Spina  D,  Harrison  S,  Page  CP .  Regulation  by  phosphodiesterase  iso-
enzymes  of  non-adrenergic  non-cholinergic  contraction in  guinea-pig
isolated  main bronchus. Br J Pharmacol 1995;  116: 2334–2340
21. Holbrook  M,  Gozzard  N,  James T,  Higgs  G,  Hughes  B.  Inhibition of
bronchospasm  and  ozone-induced  airway  hyperresponsiveness in the
guinea-pig by CDP 840, a novel phosphodiesterase type 4 inhibitor. Br
J  Pharmacol 1996;  118: 1192–1200.
22. Rabe  KF ,  Tenor  H,  Dent  G,  Schudt  C,  Liebig  S,  Magnussen  H.
Phosphodiesterase  isozymes  modulating inherent  tone  in  human  air-
ways:  identification  and  characterization.  Am  J  Physiol 1993;  264:
L458–L464.
23. Planquois  JM,  Ruffin-Morin  Y,  Lagente  V ,  Payne  AN  and  Dahl  SG.
Salbutamol potentiates the relaxant effects of selective phosphodiester-
ase  inhibitors  on  guinea-pig  isolated  trachea.  Fund  Clin  Pharmacol
1996;  10: 356–367.
Received 11 February 1999;
accepted in revised form 31 March 1999
Selective phosphodiesterase inhibitors and bronchial hyperresponsiveness
Mediators  of  Inflammation  ´  Vol  8  ´  1999 157